BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment